Insulet Corp (PODD)

Industry Medical Devices


This stock can be held in an Investment ISA and an Investment Account
Sell

$320.20

Buy

$344.00

arrow-up$2.73 (+0.85%)

Prices updated at 16 May 2025, 21:20 EDT
| Prices minimum 15 mins delay
|
Prices in USD

Insulet Corp is a medical device company based in Billerica, Massachusetts. The company develops, manufactures and sells OmniPod Insulin Management System, an insulin infusion system for people with insulin-dependent diabetes.

Income statement

20232024
1,697m2,072m
1,160m1,446m
220m309m
12.9614.91
206m418m
324m424m
Sales, General and administrative735m917m
Interest expenses36m43m
Provision for income taxes8m-118m
Operating expenses940m1,137m
Income before taxes215m300m
Net income available to common shareholders206m418m
2.965.97
Net interest income-8m-3m
Advertising and promotion--
Net investment income, net--
Realised capital gains (losses), net--
Total benefits, claims and expenses--
Earnings per share (diluted)2.945.78
Free cash flow per share-0.212.8552
Book value/share8.690115.9268
Debt equity ratio1.8648831.069742

Balance sheet

20232024
Current assets1,583m1,891m
Current liabilities451m528m
Total capital2,099m2,508m
Total debt1,416m1,392m
Total equity733m1,212m
Total non current liabilities--
Loans1,366m1,296m
Total assets2,588m3,088m
Total liabilities--
Cash and cash equivalents704m953m
Common stock70m70m

Cash flow

20232024
Cash at beginning of period690m704m
Cash dividends paid--
37m296m
Investments (gains) losses-119m-146m
704m953m
Net income--
146m430m
-109m-134m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.